Chemotherapy with or without liver-directed treatment for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a liver-directed treatment (HAI floxuridine or SIRT) to standard chemotherapy (GemOx) is more effective for people with bile duct cancer inside the liver that cannot be removed by surgery. It may be an option for those whose cancer is only in the liver or nearby lymph nodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your bile duct cancer is inside the liver and confirmed by a biopsy or previous surgery.
- Your tumors cannot be completely removed with surgery (for example, because they are too large, in a risky location, or have already come back).
- Your cancer is limited to the liver or nearby lymph nodes in the liver area that can be removed.
- You have at least one tumor that is bigger than 2 cm and can be seen on a scan.
- You are in good general health (ECOG score 0 or 1) and able to tolerate chemotherapy.
- If you are treated with HAI-FUDR, you must be willing to travel to Oslo every other week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This trial studies giving a special internal radiation treatment along with capecitabine (a chemotherapy) for liver cancer related to bile ducts, after planned surgical removal. It may help improve control of the cancer in cases where surgeons think the edges of the removed tumor may be too close.
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.